ArticleEJHaem2026
Immunophenotypically Defined Mixed-Phenotype Acute Leukemias: A Clinicopathologic Analysis of 52 Cases.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunophenotypically defined mixed-phenotype acute leukemias (MPAL) are rare and remain a diagnostic and therapeutic dilemma. We aim to explore the clinicopathologic characteristics and oncological outcomes of these entities. Methods: A total of 52 patients with immunophenotypically defined MPAL were identified from our pathology database. Medical records and archived diagnostic pathology data were retrospectively reviewed and analyzed. Results: This cohort consisted primarily of B/myeloid (80.8%), followed by T/myeloid (11.5%), B/T (5.8%), and B/T/myeloid (1.9%) immunophenotypes. There were 19 adults and 33 pediatric patients, with a male-to-female ratio of 2.1:1. A total of 34 biphenotypic and 18 bilineal MPAL patients were observed. Comparative analyses suggested that acute lymphoblastic leukemia (ALL)-directed chemotherapy, pediatric population, and biphenotypic type significantly correlated with higher complete remission rates ( Conclusion: Our findings support that immunophenotypically defined MPALs are distinctive entities with immunophenotypic diversity. Multiple factors, including treatment type, lineage component, and age group, represent strong predictors of clinical outcomes. Future studies focusing on incorporating immunophenotype and molecular profiles may contribute to better classification, prognostication, and treatment establishment.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.